--- title: "Veraxa Biotech (VRXA) news: merger" url: "https://aibio.space/companies/veraxa-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VRXA merger news: Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11. Veraxa Biotech AG (NASDAQ: VRXA), Switzerland." --- VRXA Veraxa Biotech AG NASDAQ · Switzerland # Veraxa Biotech (VRXA) news VRXA merger news Mergers · 2026-06-11 ## [Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11](https://aibio.space/news/veraxa-biotech-closes-voyager-spac-merger-nasdaq-trading-starts-june/) Veraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million. ## Latest Veraxa Biotech news 1. 2025-07-31 Mergers [Veraxa Biotech Holding AG (now Veraxa Biotech AG) files F-4 for Voyager SPAC deal](https://aibio.space/news/veraxa-biotech-holding-ag-now-veraxa-biotech-ag-files-f-4-voyager-spac/) The Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank. ## Veraxa Biotech at a glance - **Ticker**: VRXA - **Listing**: NASDAQ - **Country**: Switzerland ### Related companies - [Molecular Partners](https://aibio.space/companies/molecular-partners/) SIX: MOLN - [PolyPeptide Group](https://aibio.space/companies/polypeptide/) SIX: PPGN - [BioVersys](https://aibio.space/companies/bioversys/) SIX: BIOV - [Lonza Group](https://aibio.space/companies/lonza/) SIX: LONN - [NewcelX](https://aibio.space/companies/newcelx/) NASDAQ: NCEL - [CRISPR Therapeutics](https://aibio.space/companies/crispr-therapeutics/) NASDAQ: CRSP - [MindMaze Therapeutics Holding SA](https://aibio.space/companies/mindmaze-therapeutics/) SIX: MMTX - [Curatis Holding](https://aibio.space/companies/curatis/) SIX: CURN ### Also on NASDAQ - [Clearmind Medicine](https://aibio.space/companies/clearmind-medicine/) CMND - [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) PPCB - [Absci](https://aibio.space/companies/absci/) ABSI - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) FDMT - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX - [Vogenx](https://aibio.space/companies/vogenx/) VOGX ## What Veraxa Biotech does Veraxa Biotech AG describes itself as an oncology-focused biotechnology and clinical drug development company. Its research and development is carried out by its wholly owned subsidiary, VERAXA Biotech GmbH, based in Heidelberg, Germany. The company's technologies include antibody modulation technology from Araxa Bioscience GmbH, droplet-based microfluidic screening technology from Velabs Therapeutics GmbH, and a Hemibody platform in-licensed from Cherry Biolabs GmbH. The Hemibody platform is described as the precursor of its proprietary BiTAC-TCE platform. Through its acquisition of Synimmune GmbH, the company acquired VX-A901 (formerly FLYSIN), an antibody that the text says completed a Phase I trial for acute myeloid leukemia. Synimmune was described as active in anti-tumor antibodies for rare hematopoietic malignancies. The company's patent disclosures cover microfluidic droplet detection and sorting, relevant to its Hitmaster antibody screening technology. The filing says the business combination with PubCo was consummated on June 10, 2026, with PubCo as the surviving company after the merger. | Product or program | What it is | Stage | |---|---|---| | VX-A901 (formerly FLYSIN) | Anti-tumor antibody for acute myeloid leukemia | completed a Phase I trial | | BiTAC-TCE platform | Proprietary platform for oncology drug development, derived from the Hemibody platform | | | Hemibody platform | Platform in-licensed from Cherry Biolabs, precursor of BiTAC-TCE | | | Hitmaster microfluidic antibody screening | Microfluidics-based antibody screening technology | | Summarised from the company's [20-F filed Jun 16, 2026](https://www.sec.gov/Archives/edgar/data/2079109/000182912626006546/veraxabiotech_20f.htm). ## Questions about Veraxa Biotech Is Veraxa Biotech involved in a merger or acquisition? Our latest story on this, dated Jun 11, 2026: "Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/veraxa-biotech-closes-voyager-spac-merger-nasdaq-trading-starts-june/). What is the ticker symbol of Veraxa Biotech? Veraxa Biotech AG trades under the ticker VRXA on NASDAQ. Where is Veraxa Biotech listed? Veraxa Biotech AG is listed on NASDAQ. What is the SEC CIK of Veraxa Biotech? The SEC Central Index Key (CIK) for Veraxa Biotech AG is 2079109. Its filings are on SEC EDGAR. Which country or territory is Veraxa Biotech listed under? Our directory records Veraxa Biotech AG under Switzerland. What does Veraxa Biotech do? Our directory classifies Veraxa Biotech AG as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Veraxa Biotech? The ISIN recorded for Veraxa Biotech AG is CH1476899161. Does aibio.space cover Veraxa Biotech? aibio.space lists Veraxa Biotech AG among 2,820 public biotech companies and publishes its news here as stories appear. Where is Veraxa Biotech incorporated? SEC records list its state or country of incorporation as V8. What does Veraxa Biotech develop? Veraxa Biotech AG describes itself as an oncology-focused biotechnology and clinical drug development company. Its research and development is carried out by its wholly owned subsidiary, VERAXA Biotech GmbH, based in Heidelberg, Germany. What is VX-A901 (formerly FLYSIN) from Veraxa Biotech? VX-A901 (formerly FLYSIN): Anti-tumor antibody for acute myeloid leukemia Stage: completed a Phase I trial. What is BiTAC-TCE platform from Veraxa Biotech? BiTAC-TCE platform: Proprietary platform for oncology drug development, derived from the Hemibody platform What is the latest Veraxa Biotech (VRXA) stock news? Our latest story on Veraxa Biotech, dated Jun 11, 2026: "Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11". Veraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million. [Source](https://aibio.space/news/veraxa-biotech-closes-voyager-spac-merger-nasdaq-trading-starts-june/). How long will Veraxa Biotech's cash last? From our story of Jul 31, 2025: Veraxa's independent auditor's report for 2024 includes an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern, and the filing says the company will need substantial additional capital even after the combination closes. [Source](https://aibio.space/news/veraxa-biotech-holding-ag-now-veraxa-biotech-ag-files-f-4-voyager-spac/). Is Veraxa Biotech a smaller reporting company? SEC records list Veraxa Biotech AG's filer category as:
Emerging growth company. ## Investor discussion: Veraxa Biotech Members talk about Veraxa Biotech (VRXA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Veraxa Biotech, newest first. Each line links the filing it comes from. 1. 2026-07-31 Financings Filed a final prospectus for a securities offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/2079109/000182912626008247/veraxabiotech_f1.htm) 2. 2026-06-11 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2079109/000182912626006329/veraxabiotech_ex99-1.htm) 3. 2025-07-31 Mergers Filed documents for a merger or acquisition. SEC Form F-4. [Source](https://www.sec.gov/Archives/edgar/data/2079109/000182912625005620/veraxabiotech_f4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VRXA on TradingView](https://www.tradingview.com/symbols/NASDAQ-VRXA/). ## SEC filings and registration - **SEC name**: Veraxa Biotech AG - Post de-SPAC - **CIK**: 2079109 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: VRXA (Nasdaq), VRXAW (Nasdaq) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: TALACKER 35, ZURICH, 8001 - **Phone**: 41443858450 - **Former names**: Veraxa Biotech Holding AG ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626011185/veraxabiotechag_6k.htm) filed 2026-10-15 - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626009752/veraxabiotechag_6k.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626009237/veraxabiotechag_6k.htm) filed 2026-08-24 - [424B5](https://www.sec.gov/Archives/edgar/data/2079109/000182912626008548/veraxabiotech_424b5.htm) filed 2026-08-10 - [424B5](https://www.sec.gov/Archives/edgar/data/2079109/000182912626008547/veraxabiotech_424b5.htm) filed 2026-08-10 - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626008238/veraxabiotechag_6k.htm) filed 2026-07-31 - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626007881/veraxabiotechag_6k.htm) filed 2026-07-27 - [6-K](https://www.sec.gov/Archives/edgar/data/2079109/000182912626007854/veraxabiotechag_6k.htm) filed 2026-07-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002079109), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Veraxa Biotech AG is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VRXA, recorded under Switzerland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Veraxa Biotech AG - **Ticker**: VRXA - **Listing**: NASDAQ - **Country or territory**: Switzerland - **Business scope**: Biotechnology - **ISIN**: CH1476899161 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VRXA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/veraxa-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Veraxa Biotech (VRXA) news: merger", 2026-10-31, https://aibio.space/companies/veraxa-biotech/